Amicus Stockholders Approve Directors and Equity Plan

The latest update is out from Amicus ( (FOLD) ).

At the 2025 Annual Meeting of Stockholders held on June 5, 2025, Amicus‘s stockholders elected four Class III directors for a three-year term and approved the 2025 Equity Incentive Plan. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation on an advisory basis.

The most recent analyst rating on (FOLD) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.

Spark’s Take on FOLD Stock

According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.

Amicus Therapeutics shows promising revenue growth and strategic developments. However, challenges with profitability, high leverage, and current bearish technical indicators are concerns. The positive outlook from the earnings call and strategic corporate events provide optimism for future growth, balancing the current financial and technical challenges.

To see Spark’s full report on FOLD stock, click here.

More about Amicus

Average Trading Volume: 4,206,014

Technical Sentiment Signal: Sell

Current Market Cap: $1.93B

For a thorough assessment of FOLD stock, go to TipRanks’ Stock Analysis page.